TrialBreast cancer research and treatment2026

Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).

Meiko Nishimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.